Targeting Resident Memory T Cells for Cancer Immunotherapy
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
A novel population of memory CD8+T cells have been identified based on their phenotype (CD103, CD69) and on their local tissue residency without recirculating in the blood. These cells have been implicated in protective immune response against pathogens in both animal models and humans. Their role in cancer is just emerging as a key player in tumor immunosurveillance. Many properties of these cells suggested that it could control tumor growth : i) they respond much faster to reexposure to cognate antigen, when compared with circulating memory cells. ii) they express high levels of cytotoxic molecules iii) they are enriched in tumor specific T cells in close contact with tumor cells. TRM are present in many human cancers and are associated with a good clinical outcome independently of the infiltration of CD8+T cells. It has been recently shown that the efficacy of cancer vaccines depends on their ability to elicit TRM. In adoptive cell therapy, the transfer of cells with the ability to establish TRM at the tumor site correlated with the potency of this approach. Interestingly, TRM express checkpoint inhibitors and preliminary data showed that they could expand early during anti-PD-1 treatment and be considered as a surrogate marker of response to immunotherapy. Mucosal route of immunization, local signal to favor the recruitment of TRM or the targeting of subpopulations of dendritic cells with the ability to elicit them constitute some cues to better expand these cells for the success of cancer immunotherapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin
Mackay, L. K., Rahimpour, A., Ma, J. Z., Collins, N., Stock, A. T., Hafon, M.-L., Vega-Ramos, J., Lauzurica, P., Mueller, S. N., Stefanovic, T., et al. (2013) · Nature Immunology · doi:10.1038/ni.2744 · Cited by 1,331 · cited 10×
“) express higher amounts of inhibitory receptors (PD-1, Tim-3, CTLA-4, NKG2A, BTLA, LAG-3, SPRY1, adenosine receptor A2AR, CD39, CD101, and 2B4) and costimulatory molecules (CD27, ICOS, SIRPG, and CD137) than peripheral memory CD8+ T cells or CD8+CD103neg TIL (5, 13, 20, 34, 37).”
BackgroundInfluentialDistinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302
Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets
Sathaliyawala, T., Kubota, M., Yudanin, N., Turner, D., Camp, P., Thome, J. J. C., Bickham, K. L., Lerner, H., Goldstein, M., Sykes, M., et al. (2013) · Immunity · doi:10.1016/j.immuni.2012.09.020 · Cited by 848
Skon, C. N., Lee, J.-Y., Anderson, K. G., Masopust, D., Hogquist, K. A., & Jameson, S. C. (2013) · Nature Immunology · doi:10.1038/ni.2745 · Cited by 817 · cited 2×
“By contrast, they display low levels of sphingosine-1-phosphate receptor 1 (S1PR1) and CCR7 (5, 10), which are indispensable for tissue exit.”
BackgroundResident memory CD8 T cells trigger protective innate and adaptive immune responses
Schenkel, J. M., Fraser, K. A., Beura, L. K., Pauken, K. E., Vezys, V., & Masopust, D. (2014) · Science · doi:10.1126/science.1254536 · Cited by 731
CD49a Expression Defines Tissue-Resident CD8 + T Cells Poised for Cytotoxic Function in Human Skin
Cheuk, S., Schlums, H., Gallais Sérézal, I., Martini, E., Chiang, S. C., Marquardt, N., Gibbs, A., Detlofsson, E., Introini, A., Forkel, M., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.01.009 · Cited by 678
Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumours
Milner, J. J., Toma, C., Yu, B., Zhang, K., Omilusik, K., Phan, A. T., Wang, D., Getzler, A. J., Nguyen, T., Crotty, S., et al. (2017) · Nature · doi:10.1038/nature24993 · Cited by 677 · cited 5×
“By contrast, when antitumor CD8+ T cells that overexpress Runx3 were transferred in vivo, tumor growth was inhibited, and mice survival improved (15).”
BackgroundInfluentialDynamic T cell migration program provides resident memory within intestinal epithelium
Masopust, D., Choo, D., Vezys, V., Wherry, E. J., Duraiswamy, J., Akondy, R., Wang, J., Casey, K. A., Barber, D. L., Kawamura, K. S., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20090858 · Cited by 628
Djenidi, F., Adam, J., Goubar, A., Durgeau, A., Meurice, G., de Montpréville, V., Validire, P., Besse, B., & Mami-Chouaib, F. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402711 · Cited by 622 · cited 8×
“For example, TRM derived from NSCLC and melanoma did not express membrane CTLA-4 (19, 35), and in ovarian cancer, PD-1+CD103+CD8+ T cells exhibited a weak expression of other exhaustion-associated markers, such as CTLA-4, LAG-3, and TIM-3 (32).”
InfluentialGanesan, A.-P., Clarke, J., Wood, O., Garrido-Martin, E. M., Chee, S. J., Mellows, T., Samaniego-Castruita, D., Singh, D., Seumois, G., Alzetani, A., et al. (2017) · Nature Immunology · doi:10.1038/ni.3775 · Cited by 528 · cited 7×
“ROLe OF TRM in CAnCeR iMMUnOTHeRAPY BASeD On THe BLOCKADe OF iMMUne CHeCKPOinT MOLeCULeS TRM from healthy organs (brain, gut, lung, and skin) or localized in tumors (NSCLC, melanoma, etc.) express higher amounts of inhibitory receptors (PD-1, Tim-3, CTLA-4, NKG2A, BTLA, LAG-3, SPRY1, adenosine receptor A2AR, CD39, CD1…”
BackgroundInfluentialPrograms for the persistence, vigilance and control of human CD8+ lung-resident memory T cells
Hombrink, P., Helbig, C., Backer, R. A., Piet, B., Oja, A. E., Stark, R., Brasser, G., Jongejan, A., Jonkers, R. E., Nota, B., et al. (2016) · Nature Immunology · doi:10.1038/ni.3589 · Cited by 455
IL-2high tissue-resident T cells in the human liver: Sentinels for hepatotropic infection
Pallett, L. J., Davies, J., Colbeck, E. J., Robertson, F., Hansi, N., Easom, N. J. W., Burton, A. R., Stegmann, K. A., Schurich, A., Swadling, L., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162115 · Cited by 347
Wakim, L. M., Smith, J., Caminschi, I., Lahoud, M. H., & Villadangos, J. A. (2015) · Mucosal Immunology · doi:10.1038/mi.2014.133 · Cited by 167
Cited by
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
Blass, E., & Ott, P. A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00460-2 · Cited by 1,042
Mucosal vaccines — fortifying the frontiers
Lavelle, E. C., & Ward, R. W. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00583-2 · Cited by 752
Turning the corner on therapeutic cancer vaccines
Hollingsworth, R. E., & Jansen, K. (2019) · npj Vaccines · doi:10.1038/s41541-019-0103-y · Cited by 689
Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310
Metadata
- Authors
- Blanc, C., Hans, S., Tran, T., Granier, C., Saldman, A., Anson, M., Oudard, S., & Tartour, E.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-07-27
- Volume
- 9
- Pages
- 1722-1722
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2884980266
- Cited by
- 68
- References
- 13
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.